Search

Your search keyword '"Borch, Troels Holz"' showing total 115 results

Search Constraints

Start Over You searched for: Author "Borch, Troels Holz" Remove constraint Author: "Borch, Troels Holz"
115 results on '"Borch, Troels Holz"'

Search Results

3. Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial

4. Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial

5. Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes.

7. Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial

10. Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

11. Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

12. of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

13. Supplementary Figures 1-6 and Supplementary Table 1 from Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen

14. “One more chance to survive”The experiences of patients with advanced melanoma and their partners with Tumor-infiltrating Lymphocyte Therapy: a qualitative study and recommendations for future care

18. Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types

19. Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma

20. Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma

22. CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer

23. Changes in the tumor immune microenvironment during disease progression in patients with ovarian cancer

24. Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer

25. Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma

26. Qualitative analysis of tumor-infiltrating lymphocytes across human tumor types reveals a higher proportion of bystander CD8+ T cells in non-melanoma cancers compared to melanoma

27. Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer

28. Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8+ T Cells in Non-Melanoma Cancers Compared to Melanoma

30. Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer

32. Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses:implications for the management of irAEs

35. Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer:a pilot study

37. Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study

38. Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer:A randomized phase II study

39. Immune monitoring using mRNA-transfected dendritic cells

40. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen

41. PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine

42. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen

45. Randomized phase III study comparing non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor-infiltrating lymphocytes and interleukin-2 to standard ipilimumab treatment in metastatic melanoma.

48. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016

49. Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8 + T Cells in Non-Melanoma Cancers Compared to Melanoma.

50. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Catalog

Books, media, physical & digital resources